Eli Lilly bets $1B on India to dominate global drug exports and obesity treatment
Eli Lilly is expanding its presence in India, turning the country into a key export hub for its medications. The pharmaceutical giant has pledged over $1 billion to contract manufacturing in India, aiming to integrate the nation into its global stock market today. This move comes as the company eyes both domestic growth and international distribution for drugs like Mounjaro and future treatments.
Eli Lilly's obesity drug, Mounjaro, has quickly become its best-selling medication in India since its launch. The company is banking on its superior efficacy and competitive pricing to hold stock market share against rivals like Novo Nordisk's Wegovy. Local generics are also entering the stock market, increasing competition.
The firm is not just focusing on sales but also on partnerships. Collaborations with digital platforms and pharmaceutical companies, including Cipla, are helping Eli Lilly strengthen its reach across India. These efforts align with projections showing India could have the world's second-largest obese population by 2050, creating a significant demand for weight-loss treatments.
Beyond domestic sales, Eli Lilly plans to export medications made in India globally. Drugs like Donanemab and Orforglipron, pending regulatory approvals, will follow this export strategy. The company's investment in local manufacturing underscores its long-term commitment to India as a production and distribution centre.
Eli Lilly's expansion in India reflects both immediate stock market opportunities and long-term strategic goals. With a billion-dollar investment in manufacturing and a focus on high-demand treatments, the company is positioning itself for growth in one of the world's fastest-growing pharmaceutical markets. The move also reinforces India's role as a critical player in the global supply of Eli Lilly's medications.
